Tyler Bonkowski
Cardiovascular Disease · Dearborn, MINPI 1174185904
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.4%.
Across 140 payments — averaging $83.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eko Health, Inc.$3K
- Abbott$2K
- ZOLL Circulation Inc$2K
- AstraZeneca$918
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$813
- Cardiva Medical, Inc.$398
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$1,90016%
- Travel & lodging$2,60122%
- Food & beverage$5,89651%
- Education$4444%
- Other$8287%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eko Health, Inc. | 11 | $2,728 |
| Abbott | 29 | $2,424 |
| ZOLL Circulation Inc | 6 | $1,772 |
| AstraZeneca | 16 | $918 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $813 |
| Cardiva Medical, Inc. | 8 | $398 |
| Boston Scientific | 6 | $330 |
| Amgen | 4 | $309 |
| E.r. Squibb & Sons, L.L.C. | 3 | $253 |
| Endotronix, Inc. | 2 | $223 |
| Shockwave Medical, Inc | 4 | $222 |
| Abiomed | 2 | $158 |
| Lantheus Medical Imaging, Inc. | 6 | $153 |
| Stryker | 1 | $146 |
| Boehringer Ingelheim | 1 | $124 |
| Kestra Medical Technology Services, Inc. | 3 | $106 |
| Novo Nordisk | 2 | $88 |
| Bridgebio Pharma, Inc. | 1 | $82 |
| Pfizer | 3 | $70 |
| Inari Medical, Inc. | 2 | $54 |
| Chiesi USA, Inc. | 3 | $53 |
| Medtronic | 1 | $52 |
| Terumo Medical Corporation | 2 | $50 |
| Novartis | 2 | $41 |
| Haemonetics Corporation | 1 | $36 |
| Teleflex LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TherOx DS2 Console$1,719
- Catheter$1,719
- Downstream Cartridge$1,719
- CARDIOMEMS$1,139
- COROFLOW$381
- ENSITE$235
- OPTIS$175
- CT THROMBECTOMY SYSTEM KIT$146
- FLOWTRIEVER CATHETER, S$146
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$146
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$141
- Impella$135
- Cardiva VASCADE MVP VVCS 6-12F$125
- JARDIANCE$124
- Repatha$117
- Cardiva VASCADE 6/7F VCS$111
- LifeVest$102
How this compares
$11,670 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $31,354 |
| EntrestoSacubitril/Valsartan | 11 | $16,780 |
| Atorvastatin Calcium | 41 | $662 |
| Metoprolol Succinate | 36 | $505 |
| Losartan Potassium | 33 | $329 |
| Carvedilol | 30 | $266 |
| Rosuvastatin Calcium | 16 | $238 |
| ClopidogrelClopidogrel Bisulfate | 18 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $31,35436 claims |
| NovartisEntresto | $41 | $16,78011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$172K
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.